Introduction & Objective: Adults with type 1 diabetes (T1D) may experience severe hypoglycemic events (SHE) and impaired awareness of hypoglycemia (IAH) despite use of advanced technologies. It is unclear how a longer duration of T1D or continuous glucose monitor (CGM) use is associated with SHE.

Methods: Adult CGM users in the T1D Exchange Registry completed an online survey including SHE frequency, IAH, duration of CGM use, and years since T1D diagnosis. SHE cohorts were created based on SHE frequency in the past 12 months and presence/absence of IAH (defined in the Table). Descriptive results (mean [M], standard deviation) were reported. Bivariate correlations were used to test associations between duration of T1D or duration of CGM use with SHE frequency using Pearson’s correlation.

Results: Among 1,847 CGM users, the mean age was 45.9 years. Mean T1D duration was 29.0 years. Most participants (55.0%) used CGM for ≥5 years (Table). There were no significant associations between SHE frequency and T1D duration (r=0.03; p=0.25) or duration of CGM use (r=-0.03; p=0.15). The problematic SHE cohort reported slightly longer T1D duration (M=31.9 years) than other cohorts (M=26.8-28.6 years).

Conclusion: Severe hypoglycemia remains an important clinical risk for adults with T1D regardless of time spent living with T1D or duration of advanced monitoring technology use.

graphic
View largeDownload slide
Disclosure

A. Boateng-Kuffour: Employee; Vertex Pharmaceuticals Incorporated. P. Callahan: Employee; Vertex Pharmaceuticals Incorporated. K. Chandarana: Employee; Vertex Pharmaceuticals Incorporated. Stock/Shareholder; Vertex Pharmaceuticals Incorporated, Novo Nordisk, Eli Lilly and Company. D. Barry: Employee; Vertex Pharmaceuticals Incorporated. L. Chen: None. C.S. Kelly: None. H. Nguyen: None. K.S.M. Chapman: None. E.M. Cornelius: None. W. Wolf: None. W.H. Polonsky: Research Support; Abbott Diagnostics, Dexcom, Inc. Consultant; Eli Lilly and Company, Sanofi. Advisory Panel; embecta. Consultant; Vertex Pharmaceuticals Incorporated. Advisory Panel; 9am Health.

Funding

Vertex Pharmaceuticals Incorporated

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.